"Glioblastoma cells do not naturally produce NY-ESO-1, so the researchers administered decitabine prior to injecting the reprogrammed T cells in order to cause the tumor cells to express the NY-ESO-1 target.
"The lymphocytes will seek out and find the glioblastoma cells in the brain," said Prins, UCLA associate professor in the departments of neurosurgery and molecular and medical pharmacology. "They can cross different fiber tracts in the brain to reach tumor cells that have migrated away from the main tumor mass. These factors are important in the treatment of invasive tumors, such as glioblastoma. While surgery to remove the main tumor mass can be done, it is not possible to then locate the tumor cells that get away and this ultimately leads to a nearly universal tumor regrowth."
This new method was about 50 percent effective at curing glioblastoma in the study.
"Brain cancer cells are very good at evading the host immune system, because they do not express specific targets that can be recognized by immune cells," said Liau, UCLA professor and vice chair of neurosurgery.
"By treating glioblastoma cells with decitabine, we found that we can unmask targets on the tumor cell that can be recognized by killer T cells. Once these targets are uncovered, we can then administer T cells that are genetically programmed to attack tumor cells with the new targets."
The next stage of Prins' and Liau's research will verify these findings in other brain tumor models.
This research will be published today in the journal Neuro-Oncology."
That's great. At least the publication is not on an idiotic blogger or infamous outlet. Great find, thanks:
UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the most common and deadliest form of brain cancer.
Glioblastoma, also known as grade IV glioma, is an aggressive primary brain tumor in humans. Approximately 23,000 people in the U.S. are diagnosed with glioblastoma every year. Patients usually receive surgery, chemotherapy and radiation, but these treatments are not very effective as an estimated 50 percent of GBM patients die within one year, and 90 percent die within three years.
A study led by Dr. Robert Prins and Dr. Linda Liau, both members of the UCLA Jonsson Comprehensive Cancer Center, looked at the impact of a combined treatment using a chemotherapy drug called decitabine and genetically modified immune cells. It is a continuation of previous research, published in 2011, that focused on the effect of decitabine on glioblastoma human cell cultures.
In the new research, Prins and Liau used a technique called engineered adoptive T cell transfer, which involves extracting and growing immune cells outside of the body, then reprogramming them with the gene for a T cell receptor targeting New York esophageal squamous carcinoma, or NY-ESO-1. They are then injected back into mice with glioblastoma tumors to produce an immune response that targets the brain cancer. "
to be continued
Now antimachine aka Dan, your speculation and experience re the above statement have been proven if rrrichmond's post is correct (his conversation with ten clinic sites in the US).
Great work of both of you, thanks.
Thank you anti. Seen the usual laughing lawsuits, and some followed up by some short-bought media outlets? Desperation can only go this far, and what would be the next? LOL
At least for those who have done their DD and have always had a close eye on the company can have the opportunity to add to their positions.
Aquinox Pharmaceuticals Inc. (AQXP) is a good indication for NWBO, but we will go much much higher!
Wednesday, August 5, 2015
My Fund's performance amongst Marketocracy's Masters
Marketocracy just released the performance results of their best-regarded model Fund Managers, the Marketocracy Masters.
On average the Masters did better than the S&P500. They returned 3.01% vs 2.18% year-to-date.
The majority of Masters beat the return of the S&P500; 12 of 21 managers.
The best Marketocracy Masters performers (ytd):
#1 Branko Krstevski with 36.55% (@ a 10yr annual return of 18.4%)
#2 Wayne Himelsein with 22.69% (@ a 10yr annual return of 14.2%)
#3 Justin Uyehara with 22.23% (@ a 10yr annual return of 23.1%)
NWBO ranks the second in his fund in terms of weighting.
Always be aware of shorts, particularly those hired by the shorts who once again came out early today with well prepared lengthy FUD message in various boards as the general market sensed of a correction.
The hardest time is usually the most rewarding time in the long run. If you believe L or D or both L and D have pretty good chances of success. Remove any stop sell setting and go on working or vacating!
Only the dumbest of the dumb shorts have remained. Okay just wait a bit longer when all the covers of yours get blow away!
Shorts understand the huge stakes you will facing in losses so the intensified fud!
After July options expire, shorts will take a break to count their losses. At the time being, they are too busy to spread fud.
As warped world realizes those cart-t, and CI companies are just a hype out of proportions in valuations for their narrowly selective treatments with non durable effects. On contrary, DCVax platform will be winning the game and rewarded duly with multi-billion dollars if not hundred of billion dollars of market cap!
Have shorts done such simple DD yet? You can bet on it evidenced by their desperations! Okay, first go cleaning your millions of useless and penniless July $ 6 and $7 puts!